TrialThe Lancet. Infectious diseases2022

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.

Krishna Mohan Vadrevu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.